08. A Pharma Industry Perpective

Dr Bertil E. Lindmark, MD, PhD.
Global Head of R&D, CSO Almirall. Barcelona.

[tabs] [tab title=”Presentació ” icon=”desktop” icon_color=”#87B1B5″]
[/tab] [tab title=”Abstract” icon=”book” icon_color=”#87B1B5″]

How Personalized Should Personalized Medicine Be? A Pharma Industry Perspective

Dr Bertil E. Lindmark.
Global Head of R&D, CSO Almirall. Barcelona.


The pharmaceutical industry has moved from broad solutions for prevalent disease to more focused approaches in diseases with major unmet need and lifelong suffering. A further step is the personalization of medicine which likely will result in better benefit/risk (BR) for individuals, and in the long run both enhanced BR for larger populations, and as such an overall improved patter of distribution of benefit/risk and cost. However, in the short run the pharma industry and society will struggle to a) find cohorts of meaningful likeness which offer positive business cases b) to strike a balance between improvements for small numbers if patients and offering such for the larger mass of people who suffer disease. New technologies to characterize patients and the cost reduction of such offer possibilities to further advance personalized medicine.

[/tab] [tab title=”Currículum Vitae” icon=”briefcase” icon_color=”#87B1B5″]

Bertil Lindmark received his MD and PhD from Lund University in Sweden. Board exam specialist in Internal Medicine and in Gastroenterology, and held positions in academic medicine between 1982 and 1991. From January 2011 Chief Scientific Officer and Executive Director of R&D of Almirall, and member of the Management Board. Member of the Board of Almirall. VP and Head of Clinical Development AstraZeneca Japan, with cross-therapy area accountabilities 2009-2010. VP Clinical Development Respiratory and Inflammation Therapy Area in AstraZeneca 2001-2009. Developed Symbicort and Symbicort SMART therapy, and was accountable for more than 25 NCEs to man. Between 1991 and 2001 clinical roles in Astra and AstraZeneca, with drug development experience from all phases and all geographies, covering mainly respiratory, gastroenterology and rheumatology.

[/tab] [/tabs]

Choose your language